Matthew Feinsod's most recent trade in Kalaris Therapeutics Inc. was a trade of 135,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on March 19, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Kalaris Therapeutics Inc | Matthew Feinsod | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Mar 2026 | 135,000 | 135,000 | - | - | Stock Option (Right to Buy) | |
| Kalaris Therapeutics Inc | Matthew Feinsod | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Apr 2025 | 101,000 | 101,000 | - | - | Stock Option (Right to Buy) | |
| Kalaris Therapeutics Inc | Matthew Feinsod | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Apr 2025 | 70,551 | 70,551 | - | - | Stock Option (Right to Buy) |